Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Recruiting

Early Phase 1

Interleukin-2 & PembrolizumabLow-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Sponsor:

Emory University

Code:

NCT05493566

Conditions

Lung Non-Small Cell Carcinoma

Stage IV Lung Cancer AJCC V8

Stage IVA Lung Cancer AJCC V8

Stage IVB Lung Cancer AJCC V8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Aldesleukin

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Emory University on 2025-04-01.